Despite not differentiating itself from placebo, the Texas-based company said it plans to push pilavapadin into Phase III ...

Vivozon Pharmaceutical, a South Korean company specializing in the development and distribution of pharmaceutical drugs, is seeking to raise 250 million won ($17.2 million) as it prepares to launch ...

The company has chosen to move ahead to Phase III trials with its 10mg dose after it saw a 1.74-point reduction in pain score ...

In two randomized clinical trials evaluating pain control following abdominoplasty and bunionectomy, Journavx demonstrated ...

Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

On January 30, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid ...

Treatment for chronic pain still relies heavily on opioids. While effective, they are highly addictive and potentially deadly ...

Lexicon Pharmaceuticals is yet again defending a mixed set of data on its non-opioid pain prospect. | Lexicon Pharmaceuticals ...

Sen. Mark Kelly champions the PAIN Act to improve seniors' access to non-opioid pain treatments under Medicare.

Chronic pain is complex and difficult to treat. Prescribing opioid pain medications has become controversial but may help ...